These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38097331)

  • 21. A comprehensive search for mutations in the PKD1 and PKD2 in Japanese subjects with autosomal dominant polycystic kidney disease.
    Kurashige M; Hanaoka K; Imamura M; Udagawa T; Kawaguchi Y; Hasegawa T; Hosoya T; Yokoo T; Maeda S
    Clin Genet; 2015 Mar; 87(3):266-72. PubMed ID: 24611717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of Seminal Megavesicles, Prostate Median Cysts, and Genotype in Autosomal Dominant Polycystic Kidney Disease.
    Zhang W; Stephens CJ; Blumenfeld JD; Behzadi AH; Donahue S; Bobb WO; Newhouse JH; Rennert H; Zhao Y; Prince MR
    J Magn Reson Imaging; 2019 Mar; 49(3):894-903. PubMed ID: 30230107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exome sequencing of Saudi Arabian patients with ADPKD.
    Al-Muhanna FA; Al-Rubaish AM; Vatte C; Mohiuddin SS; Cyrus C; Ahmad A; Shakil Akhtar M; Albezra MA; Alali RA; Almuhanna AF; Huang K; Wang L; Al-Kuwaiti F; Elsalamouni TSA; Al Hwiesh A; Huang X; Keating B; Li J; Lanktree MB; Al-Ali AK
    Ren Fail; 2019 Nov; 41(1):842-849. PubMed ID: 31488014
    [No Abstract]   [Full Text] [Related]  

  • 24. Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease.
    Bae KT; Zhou W; Shen C; Landsittel DP; Wu Z; Tao C; Chapman AB; Torres VE; Yu ASL; Mrug M; Bennett WM; Harris PC;
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):823-833. PubMed ID: 31088850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.
    Lavu S; Vaughan LE; Senum SR; Kline TL; Chapman AB; Perrone RD; Mrug M; Braun WE; Steinman TI; Rahbari-Oskoui FF; Brosnahan GM; Bae KT; Landsittel D; Chebib FT; Yu AS; Torres VE; ; Harris PC
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexistence of autosomal dominant polycystic kidney disease type 1 and hereditary renal hypouricemia type 2: A model of early-onset and fast cyst progression.
    Peces R; Mena R; Peces C; Cuesta E; Selgas R; Barruz P; Lapunzina P; Nevado J
    Clin Genet; 2020 Jun; 97(6):857-868. PubMed ID: 32166738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Sekine A; Hoshino J; Fujimaru T; Suwabe T; Mizuno H; Kawada M; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Mandai S; Chiga M; Kikuchi H; Ando F; Mori T; Sohara E; Uchida S; Sawa N; Takaichi K; Ubara Y
    Am J Nephrol; 2020; 51(9):745-751. PubMed ID: 32784291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
    Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
    Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
    Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
    Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
    Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
    Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
    Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
    Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.
    Yu ASL; Shen C; Landsittel DP; Grantham JJ; Cook LT; Torres VE; Chapman AB; Bae KT; Mrug M; Harris PC; Rahbari-Oskoui FF; Shi T; Bennett WM;
    Kidney Int; 2019 May; 95(5):1253-1261. PubMed ID: 30922668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical findings, underlying pathogenetic processes and treatment of vascular dysfunction in autosomal dominant polycystic kidney disease.
    Zhu J; Liu F; Mao J
    Ren Fail; 2023; 45(2):2282027. PubMed ID: 37970664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of rapid disease progression in autosomal dominant polycystic kidney disease.
    Corradi V; Gastaldon F; Caprara C; Giuliani A; Martino F; Ferrari F; Ronco C
    Minerva Med; 2017 Feb; 108(1):43-56. PubMed ID: 27701376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.
    Cornec-Le Gall E; Audrézet MP; Rousseau A; Hourmant M; Renaudineau E; Charasse C; Morin MP; Moal MC; Dantal J; Wehbe B; Perrichot R; Frouget T; Vigneau C; Potier J; Jousset P; Guillodo MP; Siohan P; Terki N; Sawadogo T; Legrand D; Menoyo-Calonge V; Benarbia S; Besnier D; Longuet H; Férec C; Le Meur Y
    J Am Soc Nephrol; 2016 Mar; 27(3):942-51. PubMed ID: 26150605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Involvement in Patients with Autosomal Dominant Polycystic Kidney Disease: A Review.
    Pietrzak-Nowacka M; Safranow K; Płońska-Gościniak E; Nowacki A; Późniak P; Gutowski P; Ciechanowski K
    Kidney Blood Press Res; 2024; 49(1):9-19. PubMed ID: 38096797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining genotype with height-adjusted kidney length predicts rapid progression of ADPKD.
    Chen EWC; Chong J; Valluru MK; Durkie M; Simms RJ; Harris PC; Ong ACM
    Nephrol Dial Transplant; 2024 May; 39(6):956-966. PubMed ID: 38224954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autosomal dominant polycystic kidney disease (ADPKD) in Tunisia: From molecular genetics to the development of prognostic tools.
    Abdelwahed M; Hilbert P; Ahmed A; Dey M; Bouomrani S; Kamoun H; Ammar-Keskes L; Belguith N
    Gene; 2022 Apr; 817():146174. PubMed ID: 35031424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Clinical and Mutational Spectrum of 69 Turkish Children with Autosomal Recessive or Autosomal Dominant Polycystic Kidney Disease: A Multicenter Retrospective Cohort Study.
    Tutal O; Gulhan B; Atayar E; Yuksel S; Ozcakar ZB; Soylemezoglu O; Saygili S; Caliskan S; Inozu M; Baskin E; Duzova A; Hayran M; Topaloglu R; Ozaltin F
    Nephron; 2024; 148(5):319-332. PubMed ID: 36657418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.